Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CalciMedica Inc CALC

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).


NDAQ:CALC - Post by User

Post by yukon_goldon Jan 30, 2023 11:23pm
401 Views
Post# 35255610

Graycliff's Interview with Planet MicroCap for Latest Update

Graycliff's Interview with Planet MicroCap for Latest Update

WATCH BELOW:

 

CEO James Macintosh Talks Graycliff's Shakespeare and Baldwin Gold Projects in Ontario and 2023 Value Catalysts

Watch the latest interview for a brief overview and history of Graycliff Exploration, learn what makes Graycliff's gold projects stand out from its peers, and the Company's value catalysts in the near term and the year ahead.

Graycliff Exploration Limited (CSE: GRAY) Webcast | Planet MicroCap Showcase: VIRTUAL 2022

Click on the video above to watch the interview or find the video link below:

https://youtu.be/uKPO1VcZu60

 
About Graycliff Exploration Limited
 
Graycliff Exploration is a mineral exploration company focused on its 1,025 hectares of prospective ground, located roughly 80 kilometres west of Sudbury on the prolific Canadian Shield. The Company's Shakespeare Project consists of one crown patented lease, two crown leases and 40 claims on a property associated with the historic Shakespeare Gold Mine, which operated from 1903 to 1907. Graycliff’s Baldwin Project is adjacent to the east and is comprised of 68 claims covering 1,500 hectares. This brings the Company's total land package in the area to 2,525 hectares. The two projects together could be the beginning of a new Ontario Gold Camp.
 

For more information, please contact:

 

 

Iryna Zheliasko, Investor Relations

Iryna@grovecorp.ca

1-647-249-9298

Visit our website
Graycliff Exploration Limited
Nicholas D Konkin | 401 Bay Street, Suite 2702, 401 Bay Street, Suite 2702, Toronto, M5H2Y4 Canada 4165679087
<< Previous
Bullboard Posts
Next >>